Nanomedicine: Nanotechnology, Biology and Medicine
Volume 3, Issue 1 , Pages 20-31 , March 2007

The present and future of nanotechnology in human health care

  • S.K. Sahoo, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Institute of Life Sciences, Nanomedicine Laboratory, Chandrasekharpur, Bhubaneswar, Orissa, India.
    • ,
  • S. Parveen, MS
    • ,
  • J.J. Panda, MS

Received 3 March 2006 ,Revised 4 October 2006 ,Accepted 21 November 2006.

References 

  1. Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther. 2003;3:655–663
  2. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8:1112–1120
  3. Williams D. Nanotechnology: a new look. Med Device Technol. 2004;15:9–10
  4. Cheng MM, Cuda G, Bunimovich YL, Gaspari M, Heath JR, Hill HD, et al. Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol. 2006;10:11–19
  5. Matsudai M, Hunt G. Nanotechnology and public health. Nippon Koshu Eisei Zasshi. 2005;52:923–927
  6. Chan WC. Bionanotechnology progress and advances. Biol Blood Marrow Transplant. 2006;12:87–91
  7. Shaffer C. Nanomedicine transforms drug delivery. Drug Discov Today. 2005;10:1581–1582
  8. Yoshikawa T, Tsutsumi Y, Nakagawa S. Development of nanomedicine using intracellular DDS. Nippon Rinsho. 2006;64:247–252
  9. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19:311–330
  10. Emerich DF. Nanomedicine—prospective therapeutic and diagnostic applications. Expert Opin Biol Ther. 2005;5:1–5
  11. Whitesides GM. The ‘right’ size in nanobiotechnology. Nat Biotechnol. 2003;21:1161–1165
  12. Roco MC, Bainbridge W. Converging technologies for improving human performance. National Science Foundation and Department of Commerce Report. 2002;
  13. Roco MC. Nanotechnology: convergence with modern biology and medicine. Curr Opin Biotechnol. 2003;14:337–346
  14. Freitas RA. What is nanomedicine?. Dis Mon. 2005;51:325–341
  15. Sahoo SK. Applications of nanomedicine. Asia Pacific Biotech News. 2005;9:1048–1050
  16. Moghimi SM. Nanomedicine prospective diagnostic and therapeutic potentials. Asia Pacific Biotech News. 2005;9:1072–1077
  17. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4:363–374
  18. Vasir JK, Reddy MK, Labhasetwar V. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci. 2005;1:47–64
  19. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284
  20. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392
  21. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822
  22. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res. 2001;18:1157–1166
  23. Pardridge WM. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev. 1999;36:299–321
  24. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul. 1998;15:67–74
  25. Garcia-Garcia E, Gil S, Andrieux K, et al. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci. 2005;62:1400–1408
  26. Feng SS, Mu L, Win KY, et al. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:413–424
  27. Kattan J, Droz JP, Couvreur P, et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs. 1992;10:191–199
  28. de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004;34:3702–3712
  29. Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn. 2003;3:153–161
  30. Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr Opin Biotechnol. 2005;16:674–680
  31. Kubik T, Bogunia-Kubik K, Sugisaka M. Nanotechnology on duty in medical applications. Curr Pharm Biotechnol. 2005;6:17–33
  32. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol. 2005;6:3–5
  33. Orive G, Hernandez RM, Rodriguez Gascon A, Dominguez-Gil A, Pedraz JL, et al. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol. 2003;14:659–664
  34. Mazzola L. Commercializing nanotechnology. Nat Biotechnol. 2003;21:1137–1143
  35. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005;19:165–177
  36. Pawar R, Ben-Ari A, Domb AJ. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther. 2004;4:1203–1212
  37. Wilkinson JM. Nanotechnology applications in medicine. Med Device Technol. 2003;14:29–31
  38. Li KC, Pandit SD, Guccione S, Guccione S, Bednarski MD. Molecular imaging applications in nanomedicine. Biomed Microdevices. 2004;6:113–116
  39. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H, et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet. 2003;42:1089–1105
  40. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006;[In press]
  41. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs. 2005;8:77–84
  42. Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov Today. 2005;10:1435–1442
  43. Ferrari M, Downing G. Medical nanotechnology: shortening clinical trials and regulatory pathways?. BioDrugs. 2005;19:203–210
  44. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release. 2006;[In press]
  45. Mayer C. Nanocapsules as drug delivery systems. Int J Artif Organs. 2005;28:1163–1171
  46. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101–108
  47. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56:1527–1535
  48. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res. 2001;18:1521–1527
  49. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release. 2004;96:55–65
  50. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target. 2003;11:495–507
  51. Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst. 2003;20:103–137
  52. Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines. 2005;4:185–196
  53. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res. 2002;19:1480–1487
  54. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005;12:189–211
  55. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005;74:711–738
  56. Ariga T. Gene therapy for primary immunodeficiency diseases: recent progress and misgivings. Curr Pharm Des. 2006;12:549–556
  57. Rogers S. Gene therapy: a potentially invaluable aid to medicine and mankind. Res Commun Chem Pathol Pharmacol. 1971;2:587–600
  58. Ulmanen I, Kallio A. Gene therapy of somatic cells, the principle and techniques. Ann Clin Res. 1986;18:316–321
  59. Blum HE. Gene therapy—basic principles. Schweiz Rundsch Med Prax. 1995;84:34–38
  60. Hanakawa Y, Shirakata Y, Nagai H, Yahata Y, Tokumaru S, Yamasaki K, et al. Cre-loxP adenovirus-mediated foreign gene expression in skin-equivalent keratinocytes. Br J Dermatol. 2005;152:1391–1392
  61. Wells DJ. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 2004;11:1363–1369
  62. Yotsuyanagi T, Hazemoto N. Cationic liposomes in gene delivery. Nippon Rinsho. 1998;56:705–712
  63. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006;208:299–318
  64. Davis SS. Biomedical applications of nanotechnology—implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15:217–224
  65. Hart SL. Lipid carriers for gene therapy. Curr Drug Deliv. 2005;2:423–428
  66. Ewert K, Evans HM, Ahmad A, Slack NL, Lin AJ, Martin-Herranz A, et al. Lipoplex structures and their distinct cellular pathways. Adv Genet. 2005;53:119–155
  67. Simoes S, Filipe A, Faneca H, Mano M, Penacho N, Duzgunes N, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005;2:237–254
  68. Duzgunes N, De C, Ilarduya T, Simoes S, Zhdanov RI, Konopka K, et al. Cationic liposomes for gene delivery: novel cationic lipids and enhancement by proteins and peptides. Curr Med Chem. 2003;10:1213–1220
  69. Liu L, Zern MA, Lizarzaburu ME, Nantz MH, Wu J. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Ther. 2003;2:180–187
  70. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther. 2005;4:625–631
  71. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH, et al. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10:2941–2952
  72. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release. 2001;74:115–128
  73. Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther. 2002;13:761–773
  74. Pirollo KF, Hao Z, Rait A, Jang YJ, Fee WE, Ryan P. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. 1997;14:1735–1746
  75. Clark PR, Hersh EM. Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther. 1999;1:158–176
  76. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM, et al. Organ-specific gene expression in the rhesus monkey eye following intravenous nonviral gene transfer. Mol Vis. 2003;9:465–472
  77. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–651
  78. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329–347
  79. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(d,l-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16:1217–1226
  80. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002;244:105–115
  81. Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res. 2004;21:354–364
  82. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm. 2004;1:211–219
  83. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;19:1310–1316
  84. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57:2177–2202
  85. Al-Jamal KT, Ramaswamy C, Florence AT. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev. 2005;57:2238–2270
  86. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005;57:2147–2162
  87. Maksimenko AV, Mandrouguine V, Gottikh MB, Bertrand JR, Majoral JP, Malvy C. Optimisation of dendrimer-mediated gene transfer by anionic oligomers. J Gene Med. 2003;5:61–71
  88. Kukowska-Latallo JF, Raczka E, Quintana A, Chen C, Rymaszewski M, Baker JR. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther. 2000;11:1385–1395
  89. Lin H, Datar RH. Medical applications of nanotechnology. Natl Med J India. 2006;19:27–32
  90. Guccione S, Li KC, Bednarski MD. Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol. 2004;386:219–236
  91. West JL, Halas NJ. Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annu Rev Biomed Eng. 2003;5:285–292
  92. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998;281:2013–2016
  93. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol. 2004;22:47–52
  94. Chan WC, Maxwell DJ, Gao X, Bailey RE, Ham M, Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol. 2002;13:40–46
  95. Weng J, Ren J. Luminescent quantum dots: a very attractive and promising tool in biomedicine. Curr Med Chem. 2006;13:897–909
  96. Medintz IL, Uyeda HT, Goldman ER, Matoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4:435–446
  97. Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn. 2006;6:231–244
  98. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–976
  99. Zhang CY, Yeh HC, Kuroki MT, Wang TH. Single-quantum-dot-based DNA nanosensor. Nat Mater. 2005;4:826–831
  100. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538–544
  101. So MK, Xu C, Loening AM, Gambhir SS, Rao J. Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol. 2006;24:339–343
  102. Xu Y, Piston DW, Johnson CH. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci U S A. 1999;96:151–156
  103. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A. 2002;99:12617–12621
  104. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998;5385:2016–2018
  105. Kricka LJ. Microchips, microarrays, biochips and nanochips: personal laboratories for the 21st century. Clin Chim Acta. 2001;307:219–223
  106. Hutcheson GD. The first nanochips. Sci Am. 2004;290:76–83
  107. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta. 2005;358:37–54
  108. Walton ID, Norton SM, Balasingham A, He L, Oviso DF, Gupta D, et al. Particles for multiplexed analysis in solution: detection and identification of striped metallic particles using optical microscopy. Anal Chem. 2002;74:2240–2247
  109. Kong DF, Goldschmidt-Clermont PJ. Tiny solutions for giant cardiac problems. Trends Cardiovasc Med. 2005;15:207–211
  110. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol. 2006;26:435–441
  111. Popma JJ, Piana RN, Prpic R. Clinical trials in interventional cardiology. Curr Opin Cardiol. 1999;14:412–418
  112. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC. Vascular complications after balloon and new device angioplasty. Circulation. 1993;88:1569–1578
  113. Hamon M, Lecluse E, Monassier JP, Grollier G, Potier JC. Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging. 1998;13:291–301
  114. West JL, Halas NJ. Applications of nanotechnology to biotechnology commentary. Curr Opin Biotechnol. 2000;11:215–217
  115. Shi H, Tsai WB, Garrison MD, Ferrari S, Ratner BD. Template-imprinted nanostructured surfaces for protein recognition. Nature. 1999;398:593–597
  116. Sims MR. Brackets, epitopes and flash memory cards: a futuristic view of clinical orthodontics. Aust Orthod J. 1999;15:260–268
  117. Slavkin HC. Entering the era of molecular dentistry. J Am Dent Assoc. 1999;130:413–417
  118. Farr C. Biotech in periodontics: molecular engineering yields new therapies. Dent Today. 1997;16:92, 94-7.
  119. Pruzansky S. Effect of molecular genetics and genetic engineering on the practice of orthodontics [letter to the editor]. Am J Orthod. 1972;62:539–542
  120. Ure D, Harris J. Nanotechnology in dentistry: reduction to practice. Dent Update. 2003;30:10–15
  121. Freitas RA. Nanodentistry. J Am Dent Assoc. 2000;131:1559–1565
  122. Goracci G, Mori G. Micromorphological aspects of dentin. Minerva Stomatol. 1995;44:377–387
  123. Arends J, Stokroos I, Jongebloed WG, Ruben J. The diameter of dentinal tubules in human coronal dentine after demineralization and air drying. A combined light microscopy and SEM study. Caries Res. 1995;29:118–121
  124. Dourda AO, Moule AJ, Young WG. A morphometric analysis of the cross-sectional area of dentine occupied by dentinal tubules in human third molar teeth. Int Endod J. 1994;27:184–189
  125. Addy M, West N. Etiology, mechanisms, and management of dentine hypersensitivity. Curr Opin Periodontol. 1994;2:71–77
  126. Absi EG, Addy M, Adams D. Dentine hypersensitivity. A study of the patency of dentinal tubules in sensitive and non-sensitive cervical dentine. J Clin Periodontol. 1987;14:280–284
  127. Graham L. Identifying, diagnosing, and treating dentin hypersensitivity. Dent Today. 2005;24:72–73
  128. Shellhart WC, Oesterle LJ. Uprighting molars without extrusion. J Am Dent Assoc. 1999;130:381–385
  129. Fartash B, Tangerud T, Silness J, Arvidson K. Rehabilitation of mandibular edentulism by single crystal sapphire implants and overdentures: 3-12 year results in 86 patients. A dual center international study. Clin Oral Implants Res. 1996;7:220–229
  130. Webster TJ, Waid MC, McKenzie JL, Price RL, Ejiofor JU. Nanobiotechnology: carbon nanofibres as improved neural and orthopedic implants. Nanotechnology. 2004;15:48–54
  131. Price RL, Waid MC, Haberstroh KM, Webster TJ. Selective bone cell adhesion on formulations containing carbon nanofibers. Biomaterials. 2003;24:1877–1887
  132. Chun AL, Moralez JG, Fenniri H, Webster TJ. Helical rosette nanotubes: a more effective orthopedic implant material. Nanotechnology. 2004;15(Suppl.):S1–S6
  133. Webster TJ, Ergun C, Doremus RH, Siegel RW, Bizios R. Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials. 2000;21:1803–1810
  134. Webster TJ, Ergun C, Doremus RH, Siegel RW, Bizios R. Specific proteins mediate enhanced osteoblast adhesion on nanophase ceramics. J Biomed Mater Res. 2000;51:475–483
  135. Woo KM, Chen VJ, Ma PX. Nano-fibrous scaffolding architecture selectively enhances protein adsorption contributing to cell attachment. J Biomed Mater Res A. 2003;67:531–537
  136. Sato M, Webster TJ. Nanobiotechnology: implications for the future of nanotechnology in orthopedic applications. Expert Rev Med Devices. 2004;1:105–114
  137. Hoet PH, Bruske-Hohlfeld I, Salata OV. Nanoparticles—known and unknown health risks. J Nanobiotechnology. 2004;2:12
  138. Williams D. The risks of nanotechnology. Med Device Technol. 2005;16:6, 9-10.

 No conflict of interest was reported by the authors of this paper.

PII: S1549-9634(06)00342-X

doi: 10.1016/j.nano.2006.11.008

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 3, Issue 1 , Pages 20-31 , March 2007

Article Tools